<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01346683</url>
  </required_header>
  <id_info>
    <org_study_id>CHN-0002</org_study_id>
    <nct_id>NCT01346683</nct_id>
  </id_info>
  <brief_title>Study on OsseoSpeed™ TX Implants in a Chinese Population</brief_title>
  <official_title>An Open, Prospective, Multi-center Study to Evaluate the OsseoSpeed™ TX Implant With an Early Loading Protocol in Patients With Tooth Loss in the Posterior Mandible. A 3-years Follow-up Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dentsply Sirona Implants</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dentsply Sirona Implants</source>
  <brief_summary>
    <textblock>
      To investigate the clinical efficacy of OsseoSpeed™ TX implants in a Chinese population by
      evaluation of marginal bone level alteration, implant stability and implant survival in the
      posterior mandible up to 3 years after loading. Hypothesis: Early loading of the posterior
      mandible is a safe and predictable procedure.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2011</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Marginal Bone Level Alteration</measure>
    <time_frame>Evaluated 3 years after implant loading</time_frame>
    <description>Marginal Bone Level determined from radiographs and expressed as the difference from a reference point on the implant to the most coronal bone-to-implant contact on the mesial and distal aspect of the implant. Marginal Bone Level expressed in millimeters at the 3 year follow-up visit compared to values obtained at delivery of permanent restoration i.e. loading (baseline).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Implant Survival</measure>
    <time_frame>From implant placement to the follow-up 36 months after loading.</time_frame>
    <description>Implant survival rate evaluated clinically and radiographically.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Implant Stability</measure>
    <time_frame>Measured from loading of implants to the follow-up 36 months after loading.</time_frame>
    <description>Implant stability evaluated clinically/manually (recorded as stable yes/no)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Soft Tissue Status (PPD).</measure>
    <time_frame>Measured from loading of implants to the follow-up 36 months after loading.</time_frame>
    <description>Soft tissue status measured by assessment of probing pocket depth (PPD). PPD was measured at 4 different surfaces (mesial, distal, buccal and lingual) and change compared to baseline (loading) was analyzed.
A negative value = increased pocket depth.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Soft Tissue Status (BoP)</measure>
    <time_frame>Measured from loading of implants to the follow-up 36 months after loading.</time_frame>
    <description>Soft tissue status measured by assessment of bleeding on probing (BoP).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Partially Edentulous Jaw</condition>
  <arm_group>
    <arm_group_label>OsseoSpeed TX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OsseoSpeed TX implants of lengths 8-17 mm</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>OsseoSpeed TX</intervention_name>
    <description>OsseoSpeed TX implants of lengths 8-17 mm</description>
    <arm_group_label>OsseoSpeed TX</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Provision of informed consent

          2. Aged 20-75 years at enrolment

          3. History of edentulism in the posterior mandible, Kennedy classes I or II, of at least
             four months. Last natural tooth in function is canine or first bicuspid.

          4. Neighboring tooth to the planned bridge must have natural root.

          5. Presence of natural teeth, partial prosthesis and/or implants in the opposite jaw in
             contact with the planned bridge.

          6. Deemed by the investigator to have adequate bone height and a bone width of minimum
             5.5 mm.

          7. Deemed by the investigator as likely to present an initially stable implant situation

        Exclusion criteria:

          1. Unlikely to be able to comply with study procedures, as judged by the investigator

          2. Earlier graft procedures in the study area

          3. Current need for pre-surgical bone or soft tissue augmentation in the planned implant
             area.

          4. Uncontrolled pathologic processes in the oral cavity

          5. Known or suspected current malignancy

          6. History of radiation therapy in the head and neck region

          7. History of chemotherapy within 5 years prior to surgery

          8. Systemic or local disease or condition that could compromise post-operative healing
             and/or osseointegration

          9. Uncontrolled diabetes mellitus

         10. Corticosteroids or any other medication that could influence post-operative healing
             and/or osseointegration

         11. Smoking more than 10 cigarettes/day

         12. Present alcohol and/or drug abuse

         13. Involvement in the planning and conduct of the study (applies to both Astra Tech staff
             and staff at the study site)

         14. Previous enrolment in the present study.

         15. Simultaneous participation in another clinical study or participation in a clinical
             study during the last 6 months.

         16. Subjects that are unable to give informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yongsheng Zhou, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Prosthodontics, School of Stomatology, Beijing University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Prosthodontics, School of Stomatology, Beijing University</name>
      <address>
        <city>Beijing</city>
        <zip>100081</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Prosthodontics &amp; Dental Materials, Guanghua School of Stomatology, Sun Yat-Sen University</name>
      <address>
        <city>Guangzhou</city>
        <zip>510055</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Prosthodontics, College of Stomatology, Shanghai Jiao Tong University</name>
      <address>
        <city>Shanghai</city>
        <zip>200011</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Zhou J, Huang Q, Wang X, Peng D, Li Y, Zhang L, Liu J, Zhang S, Zhao K, Jiang X, Zhou Y. Early loading of splinted implants in the posterior mandible: a prospective multicentre case series. J Clin Periodontol. 2016 Mar;43(3):298-304. doi: 10.1111/jcpe.12513. Epub 2016 Mar 1.</citation>
    <PMID>26790007</PMID>
  </results_reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>May 2, 2011</study_first_submitted>
  <study_first_submitted_qc>May 2, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2011</study_first_posted>
  <results_first_submitted>February 11, 2019</results_first_submitted>
  <results_first_submitted_qc>February 11, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 10, 2019</results_first_posted>
  <last_update_submitted>September 11, 2019</last_update_submitted>
  <last_update_submitted_qc>September 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Jaw, Edentulous</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>OsseoSpeed TX</title>
          <description>OsseoSpeed TX implants of lengths 8-17 mm</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>OsseoSpeed TX</title>
          <description>OsseoSpeed TX implants of lengths 8-17 mm</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="45"/>
          </count_list>
        </analyzed>
        <analyzed>
          <units>Implants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="107"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.5" spread="10.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <units_analyzed>Participants</units_analyzed>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <class_list>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Marginal Bone Level Alteration</title>
        <description>Marginal Bone Level determined from radiographs and expressed as the difference from a reference point on the implant to the most coronal bone-to-implant contact on the mesial and distal aspect of the implant. Marginal Bone Level expressed in millimeters at the 3 year follow-up visit compared to values obtained at delivery of permanent restoration i.e. loading (baseline).</description>
        <time_frame>Evaluated 3 years after implant loading</time_frame>
        <population>Protocol deviations excluded, a total of 5 subjects (15 implants), resulting in a per protocol analysis population of 40 subjects (92 implants).
In addition a total of 2 subjects (4 implants) had radiographs were not possible measure. Giving an analysis population of 38 subjects (88 implants) for the primary outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>OsseoSpeed TX</title>
            <description>OsseoSpeed TX implants of lengths 8-17 mm</description>
          </group>
        </group_list>
        <measure>
          <title>Marginal Bone Level Alteration</title>
          <description>Marginal Bone Level determined from radiographs and expressed as the difference from a reference point on the implant to the most coronal bone-to-implant contact on the mesial and distal aspect of the implant. Marginal Bone Level expressed in millimeters at the 3 year follow-up visit compared to values obtained at delivery of permanent restoration i.e. loading (baseline).</description>
          <population>Protocol deviations excluded, a total of 5 subjects (15 implants), resulting in a per protocol analysis population of 40 subjects (92 implants).
In addition a total of 2 subjects (4 implants) had radiographs were not possible measure. Giving an analysis population of 38 subjects (88 implants) for the primary outcome measure.</population>
          <units>millimeter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Implants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Implants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.10" spread="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Implant Survival</title>
        <description>Implant survival rate evaluated clinically and radiographically.</description>
        <time_frame>From implant placement to the follow-up 36 months after loading.</time_frame>
        <population>Protocol deviations excluded, a total of 5 subjects (15 implants), resulting in a per protocol analysis population of 40 subjects (92 implants).</population>
        <group_list>
          <group group_id="O1">
            <title>OsseoSpeed TX</title>
            <description>OsseoSpeed TX implants of lengths 8-17 mm</description>
          </group>
        </group_list>
        <measure>
          <title>Implant Survival</title>
          <description>Implant survival rate evaluated clinically and radiographically.</description>
          <population>Protocol deviations excluded, a total of 5 subjects (15 implants), resulting in a per protocol analysis population of 40 subjects (92 implants).</population>
          <units>Implants</units>
          <param>Count of Units</param>
          <units_analyzed>Implants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Implants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Implant Stability</title>
        <description>Implant stability evaluated clinically/manually (recorded as stable yes/no)</description>
        <time_frame>Measured from loading of implants to the follow-up 36 months after loading.</time_frame>
        <population>Protocol deviations excluded, a total of 5 subjects (15 implants), resulting in a per protocol analysis population of 40 subjects (92 implants).</population>
        <group_list>
          <group group_id="O1">
            <title>OsseoSpeed TX</title>
            <description>OsseoSpeed TX implants of lengths 8-17 mm</description>
          </group>
        </group_list>
        <measure>
          <title>Implant Stability</title>
          <description>Implant stability evaluated clinically/manually (recorded as stable yes/no)</description>
          <population>Protocol deviations excluded, a total of 5 subjects (15 implants), resulting in a per protocol analysis population of 40 subjects (92 implants).</population>
          <units>Implants</units>
          <param>Count of Units</param>
          <units_analyzed>Implants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Implants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Soft Tissue Status (PPD).</title>
        <description>Soft tissue status measured by assessment of probing pocket depth (PPD). PPD was measured at 4 different surfaces (mesial, distal, buccal and lingual) and change compared to baseline (loading) was analyzed.
A negative value = increased pocket depth.</description>
        <time_frame>Measured from loading of implants to the follow-up 36 months after loading.</time_frame>
        <population>Protocol deviations excluded, a total of 5 subjects (15 implants), resulting in a per protocol analysis population of 40 subjects (92 implants).</population>
        <group_list>
          <group group_id="O1">
            <title>OsseoSpeed TX</title>
            <description>OsseoSpeed TX implants of lengths 8-17 mm</description>
          </group>
        </group_list>
        <measure>
          <title>Soft Tissue Status (PPD).</title>
          <description>Soft tissue status measured by assessment of probing pocket depth (PPD). PPD was measured at 4 different surfaces (mesial, distal, buccal and lingual) and change compared to baseline (loading) was analyzed.
A negative value = increased pocket depth.</description>
          <population>Protocol deviations excluded, a total of 5 subjects (15 implants), resulting in a per protocol analysis population of 40 subjects (92 implants).</population>
          <units>millimeter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Implants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Implants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.77" spread="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Soft Tissue Status (BoP)</title>
        <description>Soft tissue status measured by assessment of bleeding on probing (BoP).</description>
        <time_frame>Measured from loading of implants to the follow-up 36 months after loading.</time_frame>
        <population>Protocol deviations excluded, a total of 5 subjects (15 implants), resulting in a per protocol analysis population of 40 subjects (92 implants).</population>
        <group_list>
          <group group_id="O1">
            <title>OsseoSpeed TX</title>
            <description>OsseoSpeed TX implants of lengths 8-17 mm</description>
          </group>
        </group_list>
        <measure>
          <title>Soft Tissue Status (BoP)</title>
          <description>Soft tissue status measured by assessment of bleeding on probing (BoP).</description>
          <population>Protocol deviations excluded, a total of 5 subjects (15 implants), resulting in a per protocol analysis population of 40 subjects (92 implants).</population>
          <units>Implants</units>
          <param>Count of Units</param>
          <units_analyzed>Implants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Implants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>OsseoSpeed TX</title>
          <description>OsseoSpeed TX implants of lengths 8-17 mm</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Common cold</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Manager Global Clinical Research</name_or_title>
      <organization>Dentsply Sirona Implants, Mölndal, SWEDEN</organization>
      <phone>0046313763500</phone>
      <email>ClinicalResearchMolndal@dentsplysirona.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

